{"commentary":{"count":3,"free_build_floor":8,"listing_floor":3,"by_channel":{"x_thread":3},"note":"Indexed podcasts, YouTube videos and X posts that name this trial. A report screens them, searches for more and cites what clinicians said when it is built."},"free_build":{"available":false},"name":"SEZanne","nct_id":"NCT07155174","offer":{"currency":"USD","how":"Order at https://www.erudio.com/contact?report=sezanne-nct07155174. The price is fixed at order. We build the report after the order and deliver it when it passes our checks; if it cannot be built to our standard, nothing is charged.","price_usd":750,"size":"focused","size_rule":"Focused: 1–12 commentary sources"},"registry":{"acronym":"SEZanne","arms":[{"description":"Participants will receive ABBV-706 dose A in combination with atezolizumab, as part of the approximately 69.5 month study duration.","label":"Safety Lead-In: ABBV-706 Dose A","type":"EXPERIMENTAL"},{"description":"Participants will receive ABBV-706 dose B in combination with atezolizumab, as part of the approximately 69.5 month study duration.","label":"Safety Lead-In: ABBV-706 Dose B","type":"EXPERIMENTAL"},{"description":"Participants will receive SOC (etoposide, carboplatin, atezolizumab, and optional lurbinectedin), as part of the approximately 69.5 month study duration.","label":"Safety Lead-In: Stand of Care (SOC)","type":"EXPERIMENTAL"},{"description":"Participants will receive ABBV-706 dose A in combination with atezolizumab, as part of the approximately 69.5 month study duration.","label":"Expansion: ABBV-706 Dose A","type":"EXPERIMENTAL"},{"description":"Participants will receive ABBV-706 dose B in combination with atezolizumab, as part of the approximately 69.5 month study duration.","label":"Expansion: ABBV-706 Dose B","type":"EXPERIMENTAL"},{"description":"Participants will receive SOC (etoposide, carboplatin, atezolizumab, and optional lurbinectedin), as part of the approximately 69.5 month study duration.","label":"Expansion: SOC","type":"EXPERIMENTAL"}],"collaborators":[],"completion_date":{"date":"2031-09","type":"ESTIMATED"},"conditions":["Small Cell Lung Cancer"],"enrollment":{"count":180,"type":"ESTIMATED"},"has_results":false,"interventions":[{"name":"ABBV-706","type":"DRUG"},{"name":"Atezolizumab","type":"DRUG"},{"name":"Etoposide","type":"DRUG"},{"name":"Carboplatin","type":"DRUG"},{"name":"Carboplatin","type":"DRUG"},{"name":"Lurbinectedin","type":"DRUG"}],"last_update":"2026-10-02","lead_sponsor":"AbbVie","official_title":"A Phase 2 Randomized, Open Label, Multicenter Study to Evaluate the Optimal Dose, Safety, and Efficacy of ABBV-706 in Combination With Atezolizumab Versus Standard of Care as First-Line Treatment in Subjects With Previously Untreated Extensive Stage Small Cell Lung Cancer (ES-SCLC)","overall_status":"RECRUITING","phases":["PHASE2"],"primary_completion_date":{"date":"2029-04","type":"ESTIMATED"},"primary_outcomes":[{"measure":"Number of Participants with Adverse Events (AE)s","timeFrame":"Up to 69.5 Months"},{"measure":"Progression-Free Survival (PFS) Based on Investigator Assessment","timeFrame":"Up to Approximately 24 Months"}],"references":[],"start_date":{"date":"2025-11-25","type":"ACTUAL"},"study_type":"INTERVENTIONAL","title":"A Study to Evaluate the Optimal Dose, Adverse Events and Change in Disease Activity of Intravenous ABBV-706 in Combination With Atezolizumab Versus Standard of Care as First-Line Treatment in Adult Participants With Previously Untreated Extensive Stage Small Cell Lung Cancer","url":"https://clinicaltrials.gov/study/NCT07155174"},"report":null,"schema_id":"erudio.trial_listing","schema_version":"2.0","state":"listed","state_text":"No report yet. It can be ordered.","url":"https://www.erudio.com/trials/sezanne-nct07155174"}